Outcome of COVID-19 infection in 50 multiple myeloma patients
treated with novel drugs: single-center experience

J 2021

Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience

KREJČÍ, Marta; Luděk POUR; Zdeněk ADAM; Viera SANDECKÁ; Martin ŠTORK et al.

Základní údaje

Originální název

Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience

Autoři

KREJČÍ, Marta; Luděk POUR; Zdeněk ADAM; Viera SANDECKÁ; Martin ŠTORK; Sabina ŠEVČÍKOVÁ; Martin KREJČÍ; Zdeňka KNECHTOVÁ a Zdeněk KRÁL

Vydání

Annals of hematology, New York, Springer Verlag, 2021, 0939-5555

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.030

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/21:00122810

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Multiple myeloma; COVID-19; Novel drugs; Hospitalization; Mortality

Štítky

14110212, 14110518, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 12. 10. 2022 17:53, Mgr. Tereza Miškechová

Anotace

V originále

Infections are the primary cause of morbidity and mortality in multiple myeloma (MM) patients (pts). The aim of our retrospective analysis was to evaluate incidence and course of COVID-19 infection in a cohort of 351 MM outpatients treated with novel drugs. COVID-19 disease was detected in 50/351 pts (14%); median age was 68 years. Gender, ISS stage, and last treatment lines were as follows: male 32, female 18; ISS-I 19, ISS-II 20, ISS-III 11; daratumumab-based 15, lenalidomide-based 12, bortezomib-based 17, other 6. Positive PCR test at COVID-19 diagnosis was present in all pts; anti-myeloma treatment was interrupted. Hospitalizations for COVID-19 pneumonia were necessary for 28/50 pts (56%), 18/50 pts (36%) in standard unit (SU) 10/50 pts (20%) in intensive care unit (ICU), and 9/50 pts (18%) died. The statistically significant parameters for COVID-19 hospitalization were as follows: responsive versus non-responsive disease (p = 0.027), ECOG performance status 0-2 versus >= 3 (p = 0.014), presence of comorbidities (0-1 versus >= 2, p = 0.043). The statistically significant factors for COVID-19 death were as follows: ECOG 0-2 versus >= 3 (p = 0.001), presence of comorbidities (0-1 versus >= 2, p = 0.007), serious course of COVID-19 disease with ICU hospitalization (SU versus ICU, p = 0.001). None of the other studied risk factors was associated with poor outcome (age, gender, ISS stage, immunoparesis, type of anti-myeloma treatment). Full recovery from COVID-19 infection was observed in 41/50 pts (82%) in median of 32 days. The course of COVID-19 disease in MM pts was mostly moderate or serious with 56% of hospitalizations and 18% of deaths.

Citovat

KREJČÍ, Marta; Luděk POUR; Zdeněk ADAM; Viera SANDECKÁ; Martin ŠTORK; Sabina ŠEVČÍKOVÁ; Martin KREJČÍ; Zdeňka KNECHTOVÁ a Zdeněk KRÁL. Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience. Annals of hematology. New York: Springer Verlag, 2021, roč. 100, č. 10, s. 2541-2546. ISSN 0939-5555. Dostupné z: https://doi.org/10.1007/s00277-021-04594-w.

@article{1802378,
   author = {Krejčí, Marta and Pour, Luděk and Adam, Zdeněk and Sandecká, Viera and Štork, Martin and Ševčíková, Sabina and Krejčí, Martin and Knechtová, Zdeňka and Král, Zdeněk},
   article_location = {New York},
   article_number = {10},
   doi = {https://doi.org/10.1007/s00277-021-04594-w},
   keywords = {Multiple myeloma; COVID-19; Novel drugs; Hospitalization; Mortality},
   language = {eng},
   issn = {0939-5555},
   journal = {Annals of hematology},
   title = {Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience},
   url = {https://link.springer.com/article/10.1007%2Fs00277-021-04594-w},
   volume = {100},
   year = {2021}
}

TY  - JOUR
ID  - 1802378
AU  - Krejčí, Marta - Pour, Luděk - Adam, Zdeněk - Sandecká, Viera - Štork, Martin - Ševčíková, Sabina - Krejčí, Martin - Knechtová, Zdeňka - Král, Zdeněk
PY  - 2021
TI  - Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience
JF  - Annals of hematology
VL  - 100
IS  - 10
SP  - 2541-2546
EP  - 2541-2546
PB  - Springer Verlag
SN  - 09395555
KW  - Multiple myeloma
KW  - COVID-19
KW  - Novel drugs
KW  - Hospitalization
KW  - Mortality
UR  - https://link.springer.com/article/10.1007%2Fs00277-021-04594-w
N2  - Infections are the primary cause of morbidity and mortality in multiple myeloma (MM) patients (pts). The aim of our retrospective analysis was to evaluate incidence and course of COVID-19 infection in a cohort of 351 MM outpatients treated with novel drugs. COVID-19 disease was detected in 50/351 pts (14%); median age was 68 years. Gender, ISS stage, and last treatment lines were as follows: male 32, female 18; ISS-I 19, ISS-II 20, ISS-III 11; daratumumab-based 15, lenalidomide-based 12, bortezomib-based 17, other 6. Positive PCR test at COVID-19 diagnosis was present in all pts; anti-myeloma treatment was interrupted. Hospitalizations for COVID-19 pneumonia were necessary for 28/50 pts (56%), 18/50 pts (36%) in standard unit (SU) 10/50 pts (20%) in intensive care unit (ICU), and 9/50 pts (18%) died. The statistically significant parameters for COVID-19 hospitalization were as follows: responsive versus non-responsive disease (p = 0.027), ECOG performance status 0-2 versus >= 3 (p = 0.014), presence of comorbidities (0-1 versus >= 2, p = 0.043). The statistically significant factors for COVID-19 death were as follows: ECOG 0-2 versus >= 3 (p = 0.001), presence of comorbidities (0-1 versus >= 2, p = 0.007), serious course of COVID-19 disease with ICU hospitalization (SU versus ICU, p = 0.001). None of the other studied risk factors was associated with poor outcome (age, gender, ISS stage, immunoparesis, type of anti-myeloma treatment). Full recovery from COVID-19 infection was observed in 41/50 pts (82%) in median of 32 days. The course of COVID-19 disease in MM pts was mostly moderate or serious with 56% of hospitalizations and 18% of deaths.
ER  -

KREJČÍ, Marta; Luděk POUR; Zdeněk ADAM; Viera SANDECKÁ; Martin ŠTORK; Sabina ŠEVČÍKOVÁ; Martin KREJČÍ; Zdeňka KNECHTOVÁ a Zdeněk KRÁL. Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience. \textit{Annals of hematology}. New York: Springer Verlag, 2021, roč.~100, č.~10, s.~2541-2546. ISSN~0939-5555. Dostupné z: https://doi.org/10.1007/s00277-021-04594-w.

Přehled o publikaci